Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) Director David P. Southwell sold 10,000 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $24.05, for a total value of $240,500.00. Following the completion of the transaction, the director now owns 114,784 shares of the company’s stock, valued at $2,760,555.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Rocket Pharmaceuticals Stock Down 2.9 %
Shares of NASDAQ:RCKT opened at $22.80 on Friday. The firm has a market cap of $2.06 billion, a P/E ratio of -7.76 and a beta of 1.07. The company has a quick ratio of 7.80, a current ratio of 7.80 and a debt-to-equity ratio of 0.04. Rocket Pharmaceuticals, Inc. has a 12-month low of $14.89 and a 12-month high of $32.53. The business has a fifty day simple moving average of $27.20 and a 200 day simple moving average of $25.28.
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last announced its earnings results on Monday, February 26th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.14. During the same period in the prior year, the business earned ($0.92) EPS. Analysts predict that Rocket Pharmaceuticals, Inc. will post -2.94 earnings per share for the current year.
Institutional Trading of Rocket Pharmaceuticals
Analysts Set New Price Targets
RCKT has been the subject of a number of research reports. StockNews.com upgraded Rocket Pharmaceuticals to a “sell” rating in a research note on Friday, February 9th. JPMorgan Chase & Co. dropped their price target on Rocket Pharmaceuticals from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Tuesday, February 27th. Lifesci Capital reiterated an “outperform” rating on shares of Rocket Pharmaceuticals in a research note on Tuesday, December 26th. The Goldman Sachs Group initiated coverage on Rocket Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “neutral” rating and a $39.00 price target for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Rocket Pharmaceuticals in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $52.13.
Get Our Latest Analysis on Rocket Pharmaceuticals
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Further Reading
- Five stocks we like better than Rocket Pharmaceuticals
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Comprehensive Analysis of PayPal Stock
- About the Markup Calculator
- Intuitive Surgical Stock Can Trend Much Higher This Year
- Pros And Cons Of Monthly Dividend Stocks
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.